Patient - 医索

找到约 326 条结果

A Phase 3, Randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR or ALK mutated in non-small cell lung cancer (ATTLAS, KCSG-LU19-04)

医客学院

LBA61 Durvalumab (durva) after sequential chemoradiotherapy (CRT) in patients (pts) with unresectable stage III NSCLC Final analysis from PACIFIC-6

医客学院 - 会议报告集

LBA2 ALINA Efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK non-small cell lung cancer (NSCLC)

医客学院 - 会议报告集

Tislelizumab plus chemotherapy for patients with EGFR-mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine kinase inhibitor therapy

医客学院 - 其他

TROPHY-U-01 Cohort 3_Sacituzumab govitecan in combination with pembrolizumab in patients with mUC who progressed after platinum-based regimens

医客学院 - 会议报告集

Study EV-103 Cohort H_Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients with MIBC who are cisplatin-ineligible

医客学院 - 会议报告集

PROpel Phase III trial of olaparib and abiraterone versus placebo and abi as first-line therapy for patients with mCRPC

医客学院 - 会议报告集

posters-Health-related quality of life in previously untreated patients with aRCC_CheckMate 9ER updated results

医客学院 - 会议报告集

posters-Health-related quality of life in previously untreated patients with aRCC in CheckMate 214_Five-year follow-up results

医客学院 - 会议报告集

Phase II study of nivolumab and salvage nivolumab ipilimumab in treatment-naïve patients with advanced clear cell renal cell (HCRN GU16-260-Cohort A)_Final report

医客学院 - 会议报告集

首页
上一页
1
2
3
4
5
...
32
33
下一页
尾页

今日实时热搜